Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 8/20 | 0.50 |
| ▸ | ADH1C | P00326 | 5/20 | 0.50 |
| ▸ | PHGDH | O43175 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15595 | 1.00 | — | — | |
| SCHEMBL1679002 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL612962 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL3080635 | 1.00 | — | — | |
| SCHEMBL283931 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL13356252 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL612785 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL28469806 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL20733112 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL28251831 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056752-B1 | Catalyst activators comprising expanded anions | DOW GLOBAL TECHNOLOGIES INC (US) | 2003-06-25 | — | — | EP | claimed |
| US-20250304543-A1 | PROCESS FOR MAKING A SUBSTANTIALLY NITROSAMINE-FREE, SUBSTANTIALLY PEROXIDE-FREE, SUBSTANTIALLY COLORLESS AMINE OXIDE | BASF SE (DE) | 2025-10-02 | — | — | US | disclosed |
| EP-4536645-A1 | PROCESS FOR MAKING A SUBSTANTIALLY NITROSAMINE-FREE, SUBSTANTIALLY PEROXIDE-FREE, SUBSTANTIALLY COLORLESS AMINE OXIDE | BASF SE (DE) | 2025-04-16 | — | — | EP | disclosed |
| CN-119365447-A | Process for preparing substantially nitrosamine-free, peroxide-free, substantially colorless amine oxide | 巴斯夫欧洲公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2023237729-A1 | PROCESS FOR MAKING A SUBSTANTIALLY NITROSAMINE-FREE, SUBSTANTIALLY PEROXIDE-FREE, SUBSTANTIALLY COLORLESS AMINE OXIDE | BASF SE (DE) | 2023-12-14 | — | — | WO | disclosed |
| US-20230133581-A1 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | HIROSHIMA UNIVERSITY (JP) | 2023-05-04 | — | — | US | disclosed |
| US-10435375-B2 | CXCR4 chemokine receptor modulators | NORTHWESTERN UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| EP-1377613-B1 | METHOD OF MAKING INTERPOLYMERS AND PRODUCTS MADE THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-1412398-B1 | HIGH MELT STRENGTH POLYMERS AND METHOD OF MAKING SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| EP-0409043-A1 | Reduction of nitrosamine formation | SOLVAY INTEROX (US) | 1991-01-23 | — | — | EP | disclosed |
| US-4960934-A | Amine oxide process | ETHYL CORPORATION (US) | 1990-10-02 | — | — | US | disclosed |
| US-4942260-A | REACTION OF A TERT-AMINE WITH HYDROGEN PEROXIDE IN THE PRESENCE OF CATALYTIC CARBON DIOXIDE | ETHYL CORPORATION (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0356918-A1 | Amine oxide process | ETHYL CORPORATION (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4889954-A | DIALKYLCARBONATE CATALYST | ETHYL CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0320694-A2 | Amine oxide process | ETHYL CORPORATION (US) | 1989-06-21 | — | — | EP | disclosed |
| EP-0307184-A2 | Preparation of Amine Oxides | ETHYL CORPORATION (US) | 1989-03-15 | — | — | EP | disclosed |
| EP-0057362-B1 | DIBENZOFURANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BASF Aktiengesellschaft (DE) | 1984-06-20 | — | — | EP | disclosed |
| EP-0103277-A1 | Quaternary ammonium salts of benzofuran derivatives and fungicides containing them | BASF Aktiengesellschaft (DE) | 1984-03-21 | — | — | EP | disclosed |
| US-4376776-A | Dibenzofuran derivatives and their use for controlling fungi | BASF AKTIENGESELLSCHAFT (DE) | 1983-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435375-B2 | CXCR4 chemokine receptor modulators | CXCR4, ACKR3, CXCR3 | ADH1A 2418/4885ADH1C 3168/4885PHGDH 3868/4885 |
| US-20230133581-A1 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | PIN1, DUSP15, FKBP1A | ADH1A 1528/4885ADH1C 1539/4885PHGDH 298/4885 |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | CXCR4, ACKR3, CXCR3 | ADH1A 2418/4885ADH1C 3168/4885PHGDH 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.